Tirzepatide provides a unique approach to combating these conditions by not only helping to control blood sugar levels but also by addressing key risk factors associated with heart disease
PLoS ONE 6(3): e18138
BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability
Moving forward, the results of the phase 3 SURPASS clinical trial program demonstrated that tirzepatide was as effective and safe as other anti-diabetic agents, such as semaglutide and dulaglutide (SURPASS-2) (SURPASS J-mono), long-acting insulin analogs (degludec and glargine) (SURPASS-3,4), and placebo (SURPASS-1) (SURPASS-5), in managing T2DM diabetes [65,66,67,68,69]
For individuals with kidney or liver conditions, your Klinic provider may adjust oral Wegovy dosing accordingly
Pharmacological GLP-1RA Action Key Mechanistic Distinctions A comprehensive review published in Cell Metabolism reviewed circuits engaged by endogenous versus pharmacological GLP-1 action, highlighting key GLP-1R-positive cell types and pathways transducing metabolic and non-glycaemic GLP-1 signals
